scPharmaceuticals (NASDAQ:SCPH) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

scPharmaceuticals (NASDAQ:SCPH) released its quarterly earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05, Zacks reports. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The business had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million.

scPharmaceuticals Trading Down 1.0 %

SCPH opened at $3.01 on Friday. scPharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $5.70. The company has a market cap of $150.62 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm has a 50 day simple moving average of $3.28 and a 200 day simple moving average of $3.80.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SCPH. Maxim Group decreased their target price on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a report on Thursday.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.